The pharmaceutical industry faces a significant change driven by digital transformation. This shift promises to revolutionise drug development, patient care and operational efficiency. However, the path to digital transformation in this highly regulated and complex industry is fraught with challenges.
The Pharmaceutical Automation and Digitalisation Congress AUTOMA+ 2024 is going to provide a valuable platform for discussing industry issues and collaborative solutions. The annual event brings together leaders from the pharmaceutical sector to explore the latest trends, technologies and strategies in digital transformation. This year, the Congress is taking place on November 18-19 in Zurich, Switzerland.
Common Challenges in the Pharmaceutical Digital Transformation Journey
Regulatory Compliance. The pharmaceutical industry is one of the most heavily regulated sectors globally. Adhering to stringent regulatory requirements while implementing new digital solutions can be challenging.
Data Privacy and Security. Handling sensitive patient data and proprietary research information necessitates robust data privacy and security measures. Cybersecurity threats can compromise patient trust and intellectual property.
Complexity of Clinical Trials. Clinical trials are complex and time-consuming, involving multiple stakeholders and extensive data management. Digital transformation can streamline these processes but also introduces new challenges in managing and integrating diverse data sources.
Overcoming Obstacles: Successful Cases from AUTOMA+ 2024 Partners
At AUTOMA+ 2024, such key industry players as Merck KGaA Darmstadt Germany, PharmaLedger Association, Novo Nordisk, Almirall (the Congress Partners) and many others are going to share their experiences in automation and digitalisation.
Merck’s strategic path. Merck KGaA Darmstadt Germany is at the forefront of digital transformation in the pharmaceutical industry. During the Congress, Thomas Endress (Executive Director EMD Digital) is going to share exclusive insights on how the company has implemented a comprehensive digital strategy. It includes the use of advanced analytics, artificial intelligence and Internet of things to improve manufacturing processes, research and development and patient care. The initiatives have already led to significant improvements: enhanced existing offerings and new products, services and business models; smoother customer experience; optimised supply chain management in real time.
Digital Trust Ecosystem by PharmaLedger Association. PharmaLedger Association, a consortium of pharmaceutical companies and technology providers, is working on creating a blockchain-based platform to enhance data integrity and transparency in the pharmaceutical supply chain. Daniel Fritz (Executive Director) is joining the Congress with an engaging topic dedicated to a digital trust ecosystem in healthcare. He is going to talk about the company’s experience in digital transformation. The project aims to reduce counterfeit drugs, improve traceability and ensure the authenticity of pharmaceutical products.
Novo Nordisk’s innovative approach. Novo Nordisk is advancing chronic diseases care and management using digital transformation tools. Their projects include, for example, the development of connected insulin pens that sync with mobile apps to provide patients with diabetes with real-time data on their insulin usage and glucose levels. Additionally, the company is implementing digital platforms to streamline clinical trial processes, ensuring faster and more efficient development of new therapies. Waheed Jowiya (Digitalisation Strategy Lead) is going to be a speaker at AUTOMA+ 2024 and unveil how Novo Nordisk is transforming the industry with artificial intelligence and automation of clinical and regulatory document production and beyond.
Almirall’s Digital Evolution strategy. Almirall has embraced digital transformation to improve dermatology care. Pol Salvadó Cols (Facility Plant Director) is joining the Congress as a speaker with the topic dedicated to the company’s strategy in a pharmaceutical plant. Almirall is leveraging artificial intelligence and machine learning to accelerate drug discovery and development processes, particularly in identifying new treatments for skin diseases. More than that, one of their notable projects includes the use of digital health technologies to enhance patient outcomes in dermatological treatments. The company has developed a mobile app that helps patients manage chronic skin conditions by tracking symptoms, medication adherence and providing personalised skincare advice.
AUTOMA+ Congress: A Collaborative Platform for Pharma Leaders
The digital transformation journey in the pharmaceutical industry is complex and challenging but essential for future success. With a clear strategy, a culture of innovation and a focus on continuous improvement, the industry can unlock the full potential of this shift, leading to more efficient operations, improved patient outcomes and sustained competitive advantage. The examples of PharmaLedger Association, Merck KGaA Darmstadt Germany, Novo Nordisk and Almirall (AUTOMA+ 2024 partners) highlight the diverse and innovative approaches companies are taking nowadays.
The AUTOMA+ 2024 Congress is a pivotal event for addressing the industry challenges and fostering collaborative solutions, ensuring that the pharmaceutical companies continue to evolve and thrive in the digital age.
Ride the Digital Wave with AUTOMA+ community of industry professionals: https://automa.plus/
